NASDAQ:ALZN
Alzamend Neuro, Inc.
- Stock
Last Close
0.62
16/05 20:00
Market Cap
5.77M
Beta: -
Volume Today
94.11K
Avg: 184.60K
PE Ratio
−0.38
PFCF: −0.69
Apr '19 | Apr '20 | Apr '21 | Apr '22 | Apr '23 | ||
|---|---|---|---|---|---|---|
average inventory | -8.11K - | -8.11K 0% | ||||
average payables | 1.02M - | 716.62K 29.55% | 833.22K 16.27% | 2.02M 142.01% | ||
average receivables | 239.82K - | 105.24K 56.11% | 8.11K 92.30% | |||
book value per share | 0.00 - | 0.01 156.37% | 0.02 158.91% | 0.15 532.27% | 0.03 79.16% | |
capex per share | -0.00 - | |||||
capex to depreciation | -30.00 - | |||||
capex to operating cash flow | 0.02 - | |||||
capex to revenue | ||||||
cash per share | 0.00 - | 0.00 109.52% | 0.02 2,158.48% | 0.16 594.89% | 0.05 66.60% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.12 - | |||||
debt to equity | 0.17 - | |||||
dividend yield | ||||||
earnings yield | -0.00 - | -0.00 10.60% | -0.00 25.10% | -0.14 2,907.53% | -0.29 110.37% | |
enterprise value | 1.20B - | 1.21B 1.13% | 1.14B 5.51% | 76.81M 93.29% | 46.67M 39.24% | |
enterprise value over ebitda | -239.20 - | -273.88 14.50% | -231.30 15.55% | -6.24 97.30% | -3.14 49.60% | |
ev to operating cash flow | -1.15K - | -516.55 54.94% | -422.18 18.27% | -11.61 97.25% | -5.23 54.96% | |
ev to sales | ||||||
free cash flow per share | -0.01 - | -0.03 121.91% | -0.03 22.19% | -0.08 136.22% | -0.09 21.31% | |
free cash flow yield | -0.00 - | -0.00 121.91% | -0.00 22.19% | -0.07 3,026.38% | -0.17 132.89% | |
graham net net | -0.01 - | -0.01 19.36% | 0.01 244.45% | 0.14 1,089.52% | 0.02 83.92% | |
graham number | 0.07 - | 0.10 51.39% | 0.18 79.97% | 0.69 279.04% | 0.33 52.21% | |
income quality | 0.21 - | 0.53 147.45% | 0.54 1.03% | 0.54 0.44% | 0.60 12.10% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -31.18 - | -264.80 749.19% | -1.93K 629.22% | |||
interest debt per share | 0.01 - | 0.00 91.02% | 0.00 84.88% | |||
inventory turnover | ||||||
invested capital | 0.17 - | |||||
market cap | 1.20B - | 1.21B 1.14% | 1.15B 5.38% | 90.88M 92.07% | 51.81M 42.99% | |
net current asset value | 316.92K - | 821.71K 159.28% | 2.01M 144.97% | 13.25M 558.17% | 2.97M 77.62% | |
net debt to ebitda | 0.01 - | 0.02 139.91% | 0.32 1,477.88% | 1.14 254.63% | 0.35 69.68% | |
net income per share | -0.05 - | -0.05 10.60% | -0.06 25.10% | -0.14 127.24% | -0.15 9.58% | |
operating cash flow per share | -0.01 - | -0.03 121.91% | -0.03 22.19% | -0.07 132.47% | -0.09 23.26% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -3.24 - | -2.42 25.19% | -1.79 26.28% | -0.85 52.17% | -2.52 194.32% | |
revenue per share | ||||||
roe | -15.34 - | -5.35 65.13% | -2.59 51.68% | -0.93 64.06% | -4.89 425.82% | |
roic | -15.33 - | -5.37 64.99% | -2.17 59.49% | -0.93 57.42% | -4.88 427.36% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | 0.00 - | 0.01 156.37% | 0.02 158.91% | 0.15 532.27% | 0.03 79.16% | |
stock based compensation to revenue | ||||||
tangible asset value | 316.92K - | 821.71K 159.28% | 2.01M 144.97% | 13.35M 563.28% | 3.05M 77.19% | |
tangible book value per share | 0.00 - | 0.01 156.37% | 0.02 158.91% | 0.15 532.27% | 0.03 79.16% | |
working capital | 316.92K - | 821.71K 159.28% | 2.01M 144.97% | 13.25M 558.17% | 2.97M 77.62% |
All numbers in USD (except ratios and percentages)